- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
Dual GIP/GLP-1 Receptor Agonist · Educational Resource
Understanding Tirzepatide and Metabolic Research
Dual GIP/GLP-1 Receptor Agonist
(Synthetic Peptide)
Investigational Application
Glucose regulation, metabolic research
Administration Protocol
Subcutaneous (subQ), weekly interval
Want to learn more?
A licensed team will reach out to guide you through the research.
Book a consultation →Dual GIP/GLP-1 Receptor Agonist · Educational Resource
Understanding Tirzepatide and Metabolic Research
01 — Overview
What is Tirzepatide?
Tirzepatide is a synthetic peptide classified as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, engineered to activate both incretin hormone pathways simultaneously.
The branded formulations of tirzepatide (marketed under names such as Mounjaro and Zepbound) hold FDA approval in the United States for specific indications. The compounded formulation referenced in this educational resource is a distinct preparation and should not be assumed to carry the same regulatory status as the branded product.
Within research literature, tirzepatide is most frequently studied for its dual-pathway role in glucose metabolism and appetite-related signaling, areas summarized further below.
02 — How it works
How It Works: Dual GIP/GLP-1 Receptor Activation and Metabolic Signaling
As a dual GIP/GLP-1 receptor agonist, tirzepatide binds to and activates both incretin receptors found in the pancreas, gastrointestinal tract, and areas of the central nervous system associated with appetite regulation.
Literature describes this dual receptor activation as producing effects on insulin secretion and appetite signaling that are studied in relation to single-pathway GLP-1 agonists, distinguishing tirzepatide's investigated mechanism from earlier compound classes.
Administration in Research
In clinical literature, tirzepatide is evaluated as a subcutaneous injection administered on a weekly schedule, with dosing protocols determined by the studies' escalation design. Research contexts differ from any at-home or self-directed use.
03 — Areas of research
Summary of Investigated Research Areas
Clinical and preclinical literature evaluates tirzepatide across several key physiological parameters to map its biological interactions:
Dual Incretin Receptor Signaling
Research literature evaluates how combined GIP and GLP-1 receptor co-activation influences insulin secretion pathways in study populations.
Appetite and Satiety Signaling
Studies observe central nervous system pathways linked to appetite regulation and satiety signaling following dual incretin receptor agonism.
Glycemic Regulation Pathways
Clinical research examines glucose-dependent insulin secretion and glucagon suppression associated with dual receptor activation.
Gastric Emptying Parameters
Investigational literature reports on gastric emptying rate as one of several physiological parameters associated with tirzepatide exposure.
Body Composition Studies
Research protocols track body composition measures over the course of controlled study periods involving this compound class.
Cardiovascular Research Markers
Studies monitor cardiovascular markers in trial populations receiving dual GIP/GLP-1 receptor agonist compounds.
04 — FAQ
Frequently Asked Questions
Ano ba talaga ang Tirzepatide?
Tirzepatide is a synthetic peptide na dual GIP/GLP-1 receptor agonist. Sa research, ino-observe ang epekto nito sa parehong incretin pathways na may kinalaman sa glucose regulation at appetite signaling. Educational discussion lang ito at hindi sales o medical advice.
FDA-approved ba ito sa Pilipinas?
May FDA-approved branded formulations ang tirzepatide sa ibang bansa (tulad ng Mounjaro/Zepbound) para sa specific indications. Ang compounded na bersyon ay hiwalay na paghahanda at hindi dapat ipagpalagay na kapareho ng regulatory status ng branded product.
Ano ang pagkakaiba nito sa Semaglutide?
Ang Tirzepatide ay dual-pathway agonist (GIP at GLP-1), samantalang ang Semaglutide ay GLP-1 lamang. Pinag-aaralan sa literature ang mga pagkakaiba ng epekto ng dalawang pathway na ito.
Pwede ba akong bumili nito dito?
Ang page na ito ay para sa educational purposes lamang. Hindi kami nagbebenta ng peptides dito online — kausapin ang isang lisensyadong healthcare provider para sa tamang gabay.
05 — References
References and Academic Literature
Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.
Frías, J.P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine.
Rosenstock, J., et al. (2021). Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes. The Lancet.
i
Medical Education Disclaimer: This page is intended strictly for educational and informational purposes regarding the scientific history and development of chemical compounds. It does not constitute medical advice, promotion, or advertising of any prescription medication. Any therapeutic applications must be evaluated and managed exclusively by a licensed medical practitioner.
Getting started
How to Get Started?
1. Consult
Book a free consultation with our licensed healthcare team.
100 % online. Hassle-free. Convenient.
2. Real Human Assessment
Talk with Philippine-licensed doctors and get prescribed.
Always doctor-led—never just an online form.
Free consultation with licensed providers
3. Start your Program
Your medication is prepared and delivered to your doorstep.
No lock-ins. No hidden fees. No subscriptions.
Formulated in FDA-regulated pharmacies
4. Consistent care
Stay on track with regular weekly follow-ups. On your chosen communication platform.
Unlimited complementary follow-ups